Action Plan and Results

Advanced Therapies Strategy and Action Plan 2010-2015 

Throughout 2009, intensive analysis and reflection work has been carried out by 7 working groups (with the participation of scientific leaders, clinical researchers, research managers, representatives from patient associations and from academia), an Advisory Committee and a Governing Committee. The outcomes from this reflection process have shaped the Andalusian Initiative for Advanced Therapies’ Strategy and Action Plan for 2010 to 2015, edited and presented in May 2010 (available in this link)

Once the Strategy and Action Plan 2010-2015 was concluded, a report entitled “6 Six Years under Review: Looking back to move forward” was thoroughly prepared.The main achievements of this period 2010-2015 are certainly exposed in this report. (available in this link). 

Advanced Therapies Design and Translation Plan 2024-2027

The Advanced Therapies Design and Translation Plan 2024-2027 aims to strengthen the research, development, and clinical implementation of advanced therapies in the community.

This plan emerges as a response to the challenges and opportunities in the advanced therapies sector, where clinical application and translation into healthcare practice require meticulous, multidisciplinary, and equitable planning. The plan, which aligns with the Health Research and Innovation Strategy of Andalusia, represents a firm commitment from the Andalusian government to consolidate leadership in advanced therapies and ensure equitable access to these cutting-edge treatments for all citizens.

It is the result of collective reflection by a broad team of experts with diverse and complementary profiles, allowing for a comprehensive view of the challenges and needs of the public healthcare system. Its scope covers the period 2024-2027 and is structured around six strategic lines, 26 objectives, and a total of 102 specific actions.

The first strategic line refers to basic research aimed at generating advanced therapy medications with clinical applications and seeks to reduce the gap between basic and clinical research by establishing priority research lines and consolidating teams of researchers in public healthcare centers in Andalusia. Additionally, programs will be promoted to incorporate new researchers into the community's advanced therapies network, facilitating the translation of scientific discoveries into clinical applications.

The second line focuses on independent and commercial clinical research and inclusion in the Andalusian Health Service (SAS) portfolio, aiming to increase both commercial clinical trials in collaboration with the pharmaceutical industry and independent clinical trials in areas of interest. Furthermore, efforts will be made to incorporate advanced therapies into the SAS service portfolio, prioritizing those treatments that have demonstrated efficacy and safety.

The third strategic line emphasizes the need for professionals with the appropriate profile, trained and capable of conducting both basic and translational research as well as producing and applying advanced therapy medicinal products for patients.

The fourth line refers to strategic alliances and collaborations aimed at research, development, and clinical translation. Thus, both national and international collaborations with public and private entities will be promoted to attract funding and resources that support the development and translation of new advanced therapies. The creation of spin-offs and the transfer of knowledge to the business sector will be key elements to strengthen the innovation ecosystem. Modernizing infrastructures is crucial for the success of advanced therapies.

Accordingly, the plan outlines in its fifth strategic line the optimization of existing infrastructures, as well as the creation of new facilities focused on regulatory preclinical development and gene therapy, both ex vivo and in vivo. The integration of information systems with those of the Andalusian public healthcare system will also be ensured to improve coordination and access to these treatments.

Finally, the sixth strategic line addresses participation and humanization in advanced therapies: patients and citizens. This section emphasizes the importance of person-centered care. Active participation of patients in managing their health will be promoted, ensuring equitable and safe access to advanced therapies. Additionally, humanization strategies will be implemented in treatments, guaranteeing comprehensive and personalized care for patients, with a gender perspective included in all processes. (available in this link but only in Spanish)